eli lilly glp-1 agonist releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity Eli Lilly's Next-Generation GLP-1R Agonist

The SUSTAIN-7 trial was a randomized, open-label, active-controlled, parallel, four-armed trial

However, these strategies are often insufficient to achieve and sustain weight loss

If the BALANCE Model launches in some future year with at least 80% participation, Part D plans could drop out of the model before the final year (originally 2031), which could interrupt treatment, or require frequent plan changes for Medicare Part D enrollees to maintain access

doi: 10.1016/S0140-6736(14)61468-9 132 KimMPlattMJShibasakiTQuagginSEBackxPHSeinoSet al

GLP-1 receptor agonists improve insulin sensitivity by enhancing insulin secretion in response to glucose and lowering blood sugar levels

GLP-1 drugs are highly effective and likely to be approved for new indications in addition to obesity and diabetes